Critical assessment of variant prioritization methods for rare disease diagnosis within the rare genomes project

Sarah L. Stenton(Broad Institute), Melanie O’Leary(Broad Institute), Gabrielle Lemire(Broad Institute), Grace E. VanNoy(Broad Institute), Stephanie DiTroia(Broad Institute), Vijay Ganesh(Broad Institute), Emily Groopman(Broad Institute), Emily O’Heir(Boston Children's Hospital), Brian Mangilog(Broad Institute), Ikeoluwa Osei‐Owusu(Broad Institute), Lynn Pais(Broad Institute), Jillian Serrano(Broad Institute), Moriel Singer‐Berk(Broad Institute), Ben Weisburd(Broad Institute), Michael W. Wilson(Broad Institute), Christina Austin‐Tse(Broad Institute), Marwa Abdelhakim(King Abdullah University of Science and Technology), Azza Althagafi(Taif University), Giulia Babbi(University of Bologna), Riccardo Bellazzi(University of Pavia), Samuele Bovo(University of Bologna), Maria Giulia Carta(University of Pavia), Rita Casadio(University of Bologna), Pieter-Jan Coenen(Invitae (United States)), Federica De Paoli, Matteo Floris(University of Sassari), Manavalan Gajapathy(University of Alabama at Birmingham), Robert Hoehndorf(King Abdullah University of Science and Technology), Julius O.B. Jacobsen(Queen Mary University of London), Thomas Joseph(Tata Consultancy Services (India)), Akash Kamandula(Northeastern University), Panagiotis Katsonis(Baylor College of Medicine), Cyrielle Kint(Invitae (United States)), Olivier Lichtarge(Baylor College of Medicine), Ivan Limongelli, Yulan Lu(Children's Hospital of Fudan University), Paolo Magni(University of Pavia), Tarun Karthik Kumar Mamidi(University of Alabama at Birmingham), Pier Luigi Martelli(University of Bologna), M. Mulargia(University of Sassari), Giovanna Nicora(University of Pavia), Keith Nykamp(Invitae (United States)), Vikas Pejaver(Genomic Health (United States)), Yisu Peng(Northeastern University), Thi Hong Cam Pham(Hue University), Maurizio Podda(University of Siena), Aditya Rao(Tata Consultancy Services (India)), Ettore Rizzo, Vangala Govindakrishnan Saipradeep(Tata Consultancy Services (India)), Castrense Savojardo(University of Bologna), Peter Schols(Invitae (United States)), Yang Shen(Texas Medical Center), Naveen Sivadasan(Tata Consultancy Services (India)), Damian Smedley(Queen Mary University of London), Dorian Soru, Rajgopal Srinivasan(Tata Consultancy Services (India)), Yuanfei Sun(Texas A&M University), Uma Sunderam(Tata Consultancy Services (India)), Wuwei Tan(Texas A&M University), Naina Tiwari(Tata Consultancy Services (India)), Xiao Wang(Children's Hospital of Fudan University), Yaqiong Wang(Children's Hospital of Fudan University), Amanda M. Williams(Baylor College of Medicine), Elizabeth A. Worthey(University of Alabama at Birmingham), Rujie Yin(Texas A&M University), Yuning You(Texas A&M University), Daniel Zeiberg(Northeastern University), Susanna Zucca, Constantina Bakolitsa(University of California, Berkeley), Steven E. Brenner(University of California, Berkeley), Stephanie M. Fullerton(University of Washington), Predrag Radivojac(Northeastern University), Heidi L. Rehm(Broad Institute), Anne O’Donnell‐Luria(Massachusetts General Hospital)
Human Genomics
April 29, 2024
Cited by 18Open Access
Full Text

Abstract

BACKGROUND: A major obstacle faced by families with rare diseases is obtaining a genetic diagnosis. The average "diagnostic odyssey" lasts over five years and causal variants are identified in under 50%, even when capturing variants genome-wide. To aid in the interpretation and prioritization of the vast number of variants detected, computational methods are proliferating. Knowing which tools are most effective remains unclear. To evaluate the performance of computational methods, and to encourage innovation in method development, we designed a Critical Assessment of Genome Interpretation (CAGI) community challenge to place variant prioritization models head-to-head in a real-life clinical diagnostic setting. METHODS: We utilized genome sequencing (GS) data from families sequenced in the Rare Genomes Project (RGP), a direct-to-participant research study on the utility of GS for rare disease diagnosis and gene discovery. Challenge predictors were provided with a dataset of variant calls and phenotype terms from 175 RGP individuals (65 families), including 35 solved training set families with causal variants specified, and 30 unlabeled test set families (14 solved, 16 unsolved). We tasked teams to identify causal variants in as many families as possible. Predictors submitted variant predictions with estimated probability of causal relationship (EPCR) values. Model performance was determined by two metrics, a weighted score based on the rank position of causal variants, and the maximum F-measure, based on precision and recall of causal variants across all EPCR values. RESULTS: Sixteen teams submitted predictions from 52 models, some with manual review incorporated. Top performers recalled causal variants in up to 13 of 14 solved families within the top 5 ranked variants. Newly discovered diagnostic variants were returned to two previously unsolved families following confirmatory RNA sequencing, and two novel disease gene candidates were entered into Matchmaker Exchange. In one example, RNA sequencing demonstrated aberrant splicing due to a deep intronic indel in ASNS, identified in trans with a frameshift variant in an unsolved proband with phenotypes consistent with asparagine synthetase deficiency. CONCLUSIONS: Model methodology and performance was highly variable. Models weighing call quality, allele frequency, predicted deleteriousness, segregation, and phenotype were effective in identifying causal variants, and models open to phenotype expansion and non-coding variants were able to capture more difficult diagnoses and discover new diagnoses. Overall, computational models can significantly aid variant prioritization. For use in diagnostics, detailed review and conservative assessment of prioritized variants against established criteria is needed.


Related Papers

No related papers found

Powered by citation graph analysis